1. Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life 2014;7:572–576.
2. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, 2020.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,
et al. Mutations of the
BRAF gene in human cancer. Nature 2002;417:949–954.
4. Alvarez JGB, Otterson GA. Agents to treat
BRAF-mutant lung cancer. Drugs Context 2019;8:212566.
5. Pratilas CA, Xing F, Solit DB. Targeting oncogenic BRAF in human cancer. Curr Top Microbiol Immunol 2012;355:83–98.
6. Fisher R, Larkin J. Vemurafenib: a new treatment for
BRAF-V600 mutated advanced melanoma. Cancer Manag Res 2012;4:243–252.
7. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P,
et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085–3096.
8. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K,
et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with
BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 2013;19:5749–5757.
9. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G,
et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4:80–93.
10. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC,
et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 2015;27:240–256.
11. Kozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: how melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer 2019;1871:313–322.
12. Han J, Jun Y, Kim SH, Hoang HH, Jung Y, Kim S,
et al. Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an
in vitro tumor microfluidic ecology. Proc Natl Acad Sci U S A 2016;113:14283–14288.
13. Joshi NA, Fass JN. Sickle: a sliding-window, adaptive, quality-based trimming tool for FastQ files (version 1.33). GitHub, 2011.
14. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S,
et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15–21.
17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N,
et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078–2079.
18. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Kallberg M,
et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods 2018;15:591–594.
19. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C,
et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213–219.
20. Magi A, Tattini L, Cifola I, D'Aurizio R, Benelli M, Mangano E,
et al. EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol 2013;14:R120.
22. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139–140.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–15550.
25. Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G,
et al. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFκB-mediated inflammatory mediators. Cell Commun Signal 2020;18:156.
26. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J,
et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014;20:1965–1977.
27. Kakavand H, Rawson RV, Pupo GM, Yang JY, Menzies AM, Carlino MS,
et al. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clin Cancer Res 2017;23:6054–6061.
28. Easty DJ, Gray SG, O’Byrne KJ, O’Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res 2011;24:446–461.
29. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C,
et al. Reversible and adaptive resistance to
BRAF(V600E) inhibition in melanoma. Nature 2014;508:118–122.
32. Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff A. Wild-type
KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. Oncogene 2018;37:897–911.
33. Sun X, Li J, Sun Y, Zhang Y, Dong L, Shen C,
et al. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget 2016;7:53558–53570.
34. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M,
et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668–682.
35. Rossi A, Roberto M, Panebianco M, Botticelli A, Mazzuca F, Marchetti P. Drug resistance of
BRAF-mutant melanoma: review of up-to-date mechanisms of action and promising targeted agents. Eur J Pharmacol 2019;862:172621.
36. Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L,
et al. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export. Proc Natl Acad Sci U S A 2018;115:E8668–E8677.
37. Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci 2015;72:1249–1260.
38. Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S,
et al. Genenames.org: the HGNC and VGNC resources in 2019. Nucleic Acids Res 2019;47:D786–D792.
40. Faiao-Flores F, Alves-Fernandes DK, Pennacchi PC, Sandri S, Vicente AL, Scapulatempo-Neto C,
et al. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Oncogene 2017;36:1849–1861.
41. Ratnikov BI, Scott DA, Osterman AL, Smith JW, Ronai ZA. Metabolic rewiring in melanoma. Oncogene 2017;36:147–157.
42. Vivas-García Y, Falletta P, Liebing J, Louphrasitthiphol P, Feng Y, Chauhan J,
et al. Lineage-restricted regulation of SCD and fatty acid saturation by MITF controls melanoma phenotypic plasticity. Molecular Cell 2020;77:120–137.